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nematode parasites
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Abstract
Background
The soil-transmitted nematodes (STNs) or helminths (hookworms, whipworms, large round-
worms) infect the intestines of ~1.5 billion of the poorest peoples and are leading causes of
morbidity worldwide. Only one class of anthelmintic or anti-nematode drugs, the benzimid-
azoles, is currently used in mass drug administrations, which is a dangerous situation. New
anti-nematode drugs are urgently needed. Bacillus thuringiensis crystal protein Cry5B is a
powerful, promising new candidate. Drug combinations, when properly made, are ideal for
treating infectious diseases. Although there are some clinical trials using drug combinations
against STNs, little quantitative and systemic work has been performed to define the charac-
teristics of these combinations in vivo.
Methodology/Principal findings
Working with the hookworm Ancylostoma ceylanicum-hamster infection system, we estab-
lish a laboratory paradigm for studying anti-nematode combinations in vivo using Cry5B and
the nicotinic acetylcholine receptor (nAChR) agonists tribendimidine and pyrantel pamoate.
We demonstrate that Cry5B strongly synergizes in vivo with both tribendimidine and pyran-
tel at specific dose ratios against hookworm infections. For example, whereas 1 mg/kg
Cry5B and 1 mg/kg tribendimidine individually resulted in only a 0%-6% reduction in hook-
worm burdens, the combination of the two resulted in a 41% reduction (P = 0.020). Further-
more, when mixed at synergistic ratios, these combinations eradicate hookworm infections
at doses where the individual doses do not. Using cyathostomin nematode parasites of
horses, we find based on inhibitory concentration 50% values that a strongylid parasite pop-
ulation doubly resistant to nAChR agonists and benzimidazoles is more susceptible or
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“hypersusceptible” to Cry5B than a cyathostomin population not resistant to nAChR ago-
nists, consistent with previous Caenhorhabditis elegans results.
Conclusions/Significance
Our study provides a powerful means by which anthelmintic combination therapies can be
examined in vivo in the laboratory. In addition, we demonstrate that Cry5B and nAChR ago-
nists have excellent combinatorial properties—Cry5B combined with nAChR agonists gives
rise to potent cures that are predicted to be recalcitrant to the development of parasite resis-
tance. These drug combinations highlight bright spots in new anthelmintic development for
human and veterinary animal intestinal nematode infections.
Author summary
Intestinal nematodes are roundworm parasites of humans and animals, causing signifi-
cant morbidity in both. In humans, these parasites are leading causes of morbidity in chil-
dren, e.g., causing growth stunting, cognitive impairment, and malnutrition. Few drugs
are used to treat these parasites in humans and animals and there is increasing evidence
that the drugs are losing efficacy and/or have low efficacy. Infectious diseases are best
treated with drug combinations and not single drugs. However, there has been little work
to characterize in detail how various anti-nematode drugs combine. Here we establish a
new laboratory model to study anti-nematode drug combinations using the human hook-
worm Ancylostoma ceylanicum infection in hamsters. We show that two classes of anti-
nematode drugs, Cry5B and the nicotinic acetylcholine receptor agonists tribendimidine
and pyrantel, combine (synergize) in a way that is more powerful at specific drug ratios
than predicted from their individual impacts. Furthermore, when combined at these
ratios, these combinations completely eliminated parasites at doses where normally nei-
ther drug has that effect. Horse parasites resistant to pyrantel also appear to be hypersensi-
tive (more sensitive than wild-type parasites) to Cry5B. These characteristics predict that
combinations of Cry5B with tribendimidine or pyrantel will be extremely effective thera-
peutically and relatively recalcitrant to the development of parasite resistance.
Introduction
Soil-transmitted helminth or soil-transmitted nematode (STN) infections are caused by differ-
ent species of intestinal parasitic nematodes, mainly Ascaris lumbricoides, the hookworms Neca-
tor americanus, Ancylostoma duodenale and Ancylostoma ceylanicum, and Trichuris trichiura[1].
STNs are the most prevalent parasites of humans on earth, with approximately 1.5 billion peo-
ple, or 20% of the world’s population, infected with at least one of these parasites[2]. STN infec-
tions can cause severe morbidity especially in children, including growth stunting, intellectual
impairment, cognitive and educational deficits, malnutrition, and iron deficiency anemia; they
also have significant impacts on adults including complications with pregnancy, impaired
worker productivity and productive capacity, and weak adults[1,3]. Intestinal parasitic nema-
todes are also the most common parasites of farm and companion animals worldwide and are
significant problems in veterinary medicine. In horses, for example, strongylid parasites are
considered ubiquitous and known as a common cause of gastrointestinal disease [4].
Anti-hookworm combination therapy
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Drug treatment using anti-nematode drugs (anthelmintics) is the current strategy to con-
trol morbidity associated with STN infections but perilously relies heavily on a single class of
drug, the benzimidazoles (BZs, namely albendazole, mebendazole) [5,6]. Unfortunately, the
current efficacy of BZs is in an alarming situation: 1) only albendazole has good efficacy
against hookworm infection and neither is highly effective against the whipworm T. trichiura
[7]; 2) not all mass drug administrations are achieving encouraging results [8,9]; and 3) there
are clear examples of low BZ efficacy against both hookworms and Ascaris, even with albenda-
zole [10–13]. Relying on a single class of drug for parasitic nematode diseases is clearly a recipe
for disaster, as has been commonly seen in veterinary medicine where resistance to single drug
classes is rampant [14]. A second approved class of anti-STN (anthelmintic) drugs is the nico-
tinic acetylcholine receptor (nAChR) agonists, namely pyrantel and levamisole. However,
these have much lower efficacy than the BZs and thus are typically not used [5,6]. Tribendimi-
dine, a newer nAChR agonist that is not yet on the WHO approved drug list, has better efficacy
(similar to albendazole) and is moving forward for clinical approval [15–19]. The same classes
of drugs are commonly used against intestinal nematodes in veterinary medicine, where wide-
spread resistance of many parasites in many animal hosts is common and medically problem-
atical [14,20].
Drug combinations to delay/prevent resistance are the mainstay of the “big three” global
infectious diseases: HIV, TB, and malaria [21]. It is now only with drug combinations that there
is effective therapy against these infectious disease agents, which would otherwise rapidly
develop resistance to monotherapies. Currently, drug combinations are routinely used to target
filarial nematode diseases [22] but not STN diseases. There is clearly an increased interest in
clinical studies with anti-STN drugs in which treatment trials are compared with defined doses
of various drugs singly and in combination, often, but not always, with the goal of improving
efficacy against whipworms [16,23–27]. However, because of the limitations of carrying out
clinical studies with humans, it is difficult to carry out detailed studies regarding optimization
of combinations (e.g., studying effects of various ratios of drug combinations or studying effects
of resistant alleles on drug efficacy) with regards to efficacy and long-term resistance manage-
ment. In vivo animal models of STNs can be used to address these limitations.
Cry5B is a new class of anti-nematode compound with in vivo efficacy against hookworms
and Ascaris [28–31]. Previous studies using the laboratory free-living nematode Caenorhabditis
elegans [32] have demonstrated that Cry5B has two ideal anti-nematode combinatorial charac-
teristics with nAChR agonists levamisole, pyrantel, and tribendimidine: 1) Cry5B synergizes
with nAChR agonists to kill and intoxicate C. elegans; and 2) C. elegans resistant to nAChR
agonists are hypersusceptible or hypersensitive to Cry5B. Here, we test these combinatorial
results using parasitic nematodes, looking for synergy with hookworms in vivo and hypersensi-
tivity (hypersusceptibility) with horse small strongylid parasites in vitro. For these studies, we
develop a new system for studying in vivo anti-nematode combination therapies with Cry5B
and nAChR agonists, with promising results. This methodology also allows for optimization of
drug ratios that can be widely applied to any anti-nematode therapy and that can provide
major advances in how to best combine anti-nematode therapies for human STN and veteri-
nary medicine use.
Materials and methods
Ethics statement
Hamsters and horses were provided with food and water (ad libitum). All animal experiments
were carried out under protocols approved by either the University of California, San Diego
(UCSD; S09067), University of Massachusetts Medical School (UMMS; A-2483) or University
Anti-hookworm combination therapy
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of Kentucky (UK; 2012–1046) Institutional Animal Care and Use Committees (IACUC). All
housing and care of laboratory animals used in this study conform to the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals in Research (see 18-F22) and
all requirements and all regulations issued by the United States Department of Agriculture
(USDA), including regulations implementing the Animal Welfare Act (P.L. 89–544) as
amended (see 18-F23). Euthanasia was performed by CO2 asphyxiation, followed by bilateral
pneumothorax.
Nematode maintenance
Hookworms A. ceylanicum were maintained in golden Syrian hamsters [29,30,33,34]. The
cyathostomins in this study were maintained naturally in two different herds. The pyrantel-
susceptible cyathostomin eggs were collected from the feces of an equine herd kept without
deworming since 1979 [35]; eggs of anthelmintic resistant cyathostomins (Population S) were
collected from the feces of a herd harboring cyathostomins that are doubly resistant to pyrantel
and benzimidazoles [36].
Reagents and drugs
HD1 Cry5B spore crystal lysate (SCL) and HD1 spore lysate (SL) for in vivo studies were pro-
duced and the concentration of Cry5B protein in HD1-Cry5B SCL was determined as previ-
ously described [37]. Tribendimidine was kindly provided by Dr. Shu-Hua Xiao at the
Chinese Centers for Disease Control and Prevention. Pyrantel pamoate was purchased from
Sigma (Cat# P6210-5G). On the day of use, SL and Cry5B SCL aliquots, tribendimidine pow-
der and pyrantel pamoate powder were resuspended in distilled water right before in vivo
treatment. Cry5B SCL suspension was kept on ice until gavage. When combinations were
used, the drugs were given together in a single oral gavage. SL was used as the control for the
Cry5B dose-response experiment, but water was used as the control for other experiments.
Repeated studies in our lab have shown that SL alone has no effect on parasite burden of fecal
egg counts relative to water (manuscript in preparation). Purified Cry5B for cyathostomin
developmental inhibition assays was produced as described before [30,38] and dissolved in 20
mM HEPES (pH8.0) right before setting up the assays.
In vivo curative studies with A. ceylanicum infections in hamsters
Male hamsters were infected with standard protocol as described before [29,30,33,34]. Males
were used because we find they are much more susceptible to hookworm infection than
females. On day 17 post-inoculation (P.I.), an overnight fecal sample was collected from each
infected hamster. The number of eggs present was counted using the modified McMaster tech-
nique and the hamsters were grouped to ensure that the hamsters in each treatment group had
roughly equivalent infection levels [29]. On day 18 P.I., hamsters were individually weighed
and given the relevant treatment per os based on body weight. Anthelmintics (or water control)
were given in 0.4 mL volume in sterile double-distilled water (3–5 hamsters per group)
through a blunt-ended gavage needle. On day 21 P.I., an overnight fecal sample was collected
from each infected hamster. The hamsters were sacrificed on day 22 P.I., and parasite burdens
and eggs per gram of feces were determined as described [29].
In vitro developmental inhibition assays with cyathostomins
Horse fecal samples harboring wild-type or double resistant cyathostomins eggs were collected
fresh in airtight plastic baggies, transported in coolers to the laboratory, packed, and shipped
Anti-hookworm combination therapy
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with ice packs to UMASS Medical School for egg isolation. Upon arrival, cyathostomin eggs
were isolated using a modified nematode egg isolation protocol [39]. Larval development
inhibition assays were set up in 96-well plates with purified Cry5B and pyrantel pamoate as
described before for the Caenorhabditis elegans larval intoxication assay [40], except ~30
cyathostomin eggs were added to each well instead of C. elegans L1 larvae. Plates were incu-
bated at 28˚ for 7 days. Each experiment included triplicate wells at each dose of Cry5B or pyr-
antel, and the experiment was performed three times independently.
Statistical and synergy analyses
All the in vivo and in vitro data were plotted with Prism 7 (GraphPad Software, California,
USA) and numerically presented in Tables 1, 2, 3, S1, and S2. The 95% confidence limits (given
in S3 Table) and percentage reductions of the in vivo experiments shown in tables were calcu-
lated with Prism 7 and Microsoft Excel, respectively. We ran Shapiro-Wilk to test for normality
of the data, and the data generally fit a normal distribution. However, to address any potential
issues with non-normality, the in vivo data were analyzed by R statistical software [41] using a
rank-based nonparametric multiple contrast test procedure by Konietschke and Pauly [42].
These are the values reported in the text. The in vivo data in all figures was also analyzed by IBM
SPSS Statistics v. 26 one-way ANOVA with one-tailed Dunnett’s post-test adjustment. Both sets
of values are reported in the tables. For both analyses, each data point was compared relative to
placebo control (water). The cyathostomin in vitro data statistical analyses (IC50 values and 95%
confidence limit calculations) were carried out with R statistical software.
Results
Cry5B and tribendimidine are synergistic in vivo
Synergism is used to describe the situation where the addition of one agent apparently
increases the effect of another so that the effect of a combination is greater than would be
Table 1. In vivo data associated with experimental results in Fig 3.
Treatment Hookworm burden
(% reduction) a
P b P c Fecal egg counts
(% reduction) d
P b P c
Control (water) 22.3 na na 2072 na na
0.33 mg/kg Cry5B 24.9 (-11.7) 0.99 0.99 1689 (18.5) 0.80 0.51
1 mg/kg Cry5B 24.3 (-9.0) 0.98 0.98 2150 (-3.8) 0.98 0.93
0.33 mg/kg TrBD 25.8 (-15.7) 0.99 1.00 1816 (12.4) 0.78 0.66
1 mg/kg TrBD 20.9 (6.3) 0.69 0.76 1534 (26.0) 0.66 0.31
0.33 mg/kg Cry5B
+ 0.33 mg/kg TrBD
15.9 (28.7) 0.13 0.12 1153 (44.4) 0.20 0.05
0.33 mg/kg Cry5B
+ 1 mg/kg TrBD
21.4 (4.0) 0.74 0.81 1316 (36.5) 0.38 0.12
1 mg/kg Cry5B
+ 0.33 mg/kg TrBD
17.1 (23.3) 0.21 0.23 1425 (31.2) 0.42 0.20
1 mg/kg Cry5B
+ 1 mg/kg TrBD
13.1 (41.3) 0.020 0.01 831 (60.0) 0.056 0.006
a Average hookworm burdens (% reduction relative to water control)
b P value relative to water control, non-parametric comparison. See Materials and Methods.
c P value relative to water control, parametric comparison. See Materials and Methods.
d Average fecal egg counts (% reduction relative to water control)
na: not applicable
TrBD = Tribendimidine
https://doi.org/10.1371/journal.pntd.0006506.t001
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expected if additive. We had two goals for studying Cry5B and tribendimidine in vivo: 1) to
determine if they are synergistic, as they are against the free-living nematode C. elegans “in
vitro” [32]; and 2) to determine which ratio of Cry5B and tribendimidine may be more syner-
gistic since the degree of synergy for these two anti-nematode compounds against C. elegans
changes based upon the ratio of the drugs [32]. Methods for quantitating synergy include
checkerboards, isobolograms, and the combination index method [43–46]. However, we
found that these methods are not ideally suited for measuring synergy for STN infections in
vivo because the high natural variation of worm burdens that occur in laboratory animals
would require using large number of animals for such a study. Indeed, in contrast to other
studies [47,48], a preliminary study we carried out using the combinatorial index method to
study in vivo synergy with these drugs failed to give an interpretable result for these reasons.
We therefore devised a different method for studying drug synergy against STNs in vivo.
We decided on an amalgam of approaches discussed in Poch and Holzmann [49,50] and
Chou [51]. In the former papers the response to drug A over a range of doses is studied in
combination with a fixed, but active, amount of drug B. Chou conversely discusses the concept
of drug enhancement/potentiation/ augmentation, in which drug A at some active dose is
combined with drug B at a dose that by itself has no effect. In our hybrid approach, we set out
to test what would happen if we study the full dose response of drug A with and without the
Table 2. In vivo data associated with experimental results in Fig 6.
Treatment Hookworm burden
(% reduction) a
P b P c Fecal egg counts
(% reduction) d
P b P c
Control (water) 37.3 na na 3194 na na
0.33 mg/kg PYR 33.5 (10.1) 0.74 0.75 2094 (34.4) 0.45 0.16
0.33 mg/kg Cry5B 33.3 (10.7) 0.79 0.74 2381 (25.5) 0.54 0.33
1 mg/kg Cry5B 32.8 (12.1) 0.78 0.71 2681 (16.1) 0.76 0.57
3 mg/kg Cry5B 39.8 (-6.7) 0.96 0.95 2556 (20.0) 0.71 0.47
9 mg/kg Cry5B 24.0 (35.7) 0.12 0.21 1575 (50.7) 0.21 0.025
0.33 mg/kg PYR
+ 0.33 mg/kg Cry5B
31.8 (14.8) 0.68 0.65 2325 (27.2) 0.56 0.29
0.33 mg/kg PYR
+ 1 mg/kg Cry5B
15.8 (57.6) 0.031 0.02 1850 (42.1) 0.24 0.070
0.33 mg/kg PYR
+ 3 mg/kg Cry5B
25.3 (32.2) 0.35 0.26 1900 (40.5) 0.34 0.084
0.33 mg/kg PYR
+ 9 mg/kg Cry5B
12.0 (67.8) 0.030 0.008 813 (74.6) 0.080 0.001
a Average hookworm burdens (% reduction relative to water control)
b P value relative to water control, non-parametric comparison. See Materials and Methods.
c P value relative to water control, parametric comparison. See Materials and Methods.
d Average fecal egg counts (% reduction relative to water control)
na: not applicable
PYR = Pyrantel
https://doi.org/10.1371/journal.pntd.0006506.t002
Table 3. Inhibitory concentration 50% (IC50) values in μg/mL with standard error for two cyathostomin lines treated with either pyrantel or Cry5B.
Susceptible
(Barn 10)
Pyrantel-resistant (Population S) P value
IC50 on pyrantel 21.9 ± 5.2 65.8 ± 23.7 <0.001
IC50 on Cry5B 10.8 ± 1.4 7.7 ± 0.86 0.033
https://doi.org/10.1371/journal.pntd.0006506.t003
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presence of no-effect or low-effect doses of drug B. As covered in the Results and Discussion
below, this methodology ends up with significant advantages.
To begin with, we defined the dose response of hookworm A. ceylanicum infections in
immunocompetent hamsters to each of these anti-nematode compounds. This parasite was
chosen 1) because hookworms are the most important of the STNs, 2) because A. ceylanicum is
a human pathogen and is increasingly recognized as major human hookworm parasite in
Southeast Asia [52–54], 3) because of its close phylogenetic relationship to the other major
hookworm parasites of humans (Ancylostoma duodenale and Necator americanus [55]), and 4)
because it is a very good system for hookworm disease study [33].
We performed dose response of A. ceylanicum infections in hamsters to tribendimidine
(Fig 1). We chose 3X change between doses for these studies since it allows for getting a good
range of doses with a fixed number of groups (e.g., vs. 2X change between doses) while still giv-
ing good discrimination of dose-responsiveness (e.g., vs. 10X change between doses). We
chose as our upper dose (strong effect) 9 mg/kg tribendimidine based on previous literature
[47] and went down factors of three to include 3 mg/kg and 1 mg/kg.
As shown in Fig 1A and 1B and S1 Table, a dose response to tribendimidine is seen. At 1
mg/kg tribendimidine relative to water control, the changes seen (actually 2% increase in
hookworm burdens, P = 0.66 and 25.5% increase in fecal egg counts, P = 0.65) are not signifi-
cant and within the normal variation given the group size. At 3 mg/kg tribendimidine, a reduc-
tion (21.6%) in hookworm burdens is seen that is not significant but approaches significance
(P = 0.063). At 9 mg/kg tribendimidine, a large and significant reduction (84%; P = 0.008) in
hookworm burdens is seen. These trends were largely confirmed in independent experiments
that also included lower doses of the drug (Fig 1C, 1D, 1E and 1F; S1 Table). Based on these
data, we concluded that 0.33 mg/kg and 1 mg/kg tribendimidine are the highest doses in this
experiment that show no detectable impact on the parasites and are safe to use as “no effect
doses” (as noted above, although 3 mg/kg tribendimidine data did not achieve statistical signif-
icance, this dose did appear to give a weak and reproducible impact on the parasites). These
data also provide a good range (0.33–9 mg/kg) of tribendimidine doses that define a range of
no effect to strong effect.
We similarly performed dose response of A. ceylanicum infections in hamsters to Cry5B
(delivered as SCL from Bacillus thuringiensis [37]). No detectable impact on hookworm bur-
dens or fecal egg counts was seen with Cry5B relative to SL control at 0.33 mg/kg Cry5B (12%
increase in hookworm burdens, P = 0.98; 1.2% decrease in fecal egg counts, P = 0.81; Fig 2A
and 2B; S1 Table). A small but not significant impact was seen at 1 mg/kg Cry5B (25% reduc-
tion in hookworm burdens, P = 0.46; 32% reduction in fecal egg counts, P = 0.45; Fig 2A and
2B; S1 Table). Previous experiments in the lab suggested that 1 mg/kg Cry5B delivered as SCLs
does not have a significant impact, which was confirmed in subsequent experiments in this
study (Figs 3 and 6). Although 3 mg/kg Cry5B did not have a statistically significant impact, it
did seem to be part of a trend in increased efficacy between 1 mg/kg Cry5B and 9 mg/kg
Cry5B, which did have a significant impact (74% reduction in hookworm burdens, P = 0.05;
Fig 2A and 2B; S1 Table). Based on these data, we chose the 0.33 mg/kg and 1 mg/kg Cry5B
doses as the highest doses that show no detectable impact on the parasites and 0.33 mg/kg up
to 9 mg/kg as a range of Cry5B doses that define a range of no effect to strong effect.
A dose response of Cry5B (0.33, 1.0, 3.0 and 9.0 mg/kg) to hookworm infections in ham-
sters was then carried out without and with the two no-effect doses of tribendimidine (0.33
and 1.0 mg/kg), measuring hookworm burdens and fecal egg counts (S1A and S1B Fig; S2
Table). These combinations give Cry5B:tribendimidine ratios ranging from 1:3–27:1. We also
carried out the reciprocal experiment in which a dose response of tribendimidine (0.33, 1.0,
3.0 and 9.0 mg/kg) to hookworm infections in hamsters was then carried out without and with
Anti-hookworm combination therapy
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Fig 1. Dose response of tribendimidine against hookworm A. ceylanicum infections in hamsters. (A), (C), and (E): Effects of tribendimidine at indicated doses on
intestinal hookworm burdens in hookworm-infected hamsters. For (A), (C), and (E) and in similar figures below, the hookworm burdens in each hamster are indicated
Anti-hookworm combination therapy
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the two no-effect doses of Cry5B (0.33 and 1.0 mg/kg), measuring hookworm burdens and
fecal egg counts (S1C and S1D Fig; S2 Table).
Qualitatively, certain trends were visible. Most notably, whereas neither 0.33 mg/kg triben-
dimidine nor 0.33 mg/kg Cry5B gave any reduction in hookworm burden in either experiment
relative to water control (in all cases the burdens were 2–27% higher than water control), the
combination of 0.33 mg/kg tribendimidine plus 0.33 mg/kg Cry5B gave a 26%-31% reduction
in hookworm burdens relative to water control (S2 Table). This (0.33 mg/kg + 0.33 mg/kg)
combination showed better efficacy than 1 mg/kg of Cry5B alone (0%-8% reduction), 1 mg/kg
tribendimidine alone (0%-18% reduction), or some other combinations, such as 0.33 mg
Cry5B plus 1 mg/kg tribendimidine (0%-20% reduction) or 1 mg Cry5B plus 0.33 mg/kg tri-
bendimidine (22%-24% reduction), all of which have more drug. Similarly, 1 mg/kg Cry5B
alone or 1 mg/kg tribendimidine alone had no significant impact (0–18% reduction) relative
to placebo (water) whereas the combination of the two at 1 mg/kg again showed a qualitatively
higher impact (33%-49% reduction).
To increase the statistical power of our analyses, we combined the data from both experi-
ments in which the same doses of each drug alone or in combination were given in both exper-
iments (combining the data doubles the number of animals in each condition, which increases
power). As shown (Fig 3A and 3B; Table 1), whereas none of the individual treatments (0.33
mg/kg of either Cry5B or tribendimidine or 1.0 mg/kg of either Cry5B or tribendimidine)
were significantly different than placebo (P0.69 for hookworm burden 0%-6% reduction;
P0.66 for fecal egg counts, 0%-26% reduction), the combination of Cry5B 1 mg/kg plus tri-
bendimidine 1 mg/kg was significantly different from placebo control (for hookworm burdens
41% reduction, P = 0.020; for fecal egg counts 60% reduction, P = 0.056). These analyses show
the two compounds are statistically synergistic. The other combination at 1:1 ratio (0.33 mg/
kg Cry5B plus 0.33 mg/kg tribendimidine) approached statistical significance: P = 0.13 and
0.20 for hookworm burden (29% reduction) and fecal egg counts (44% reduction) respectively.
In addition, this combination showed better efficacy in terms of both hookworm burden and
fecal egg counts compared to either individual drug alone at a 3X higher dose of 1 mg/kg (0%-
6% reduction in hookworm burdens; 0%-26% reduction in fecal egg counts). Both of the other
combination ratios present in this combined analyses (1:3 and 3:1 tribendimidine:Cry5B) were
also inferior in terms of their impact (4%-23% reduction in hookworm burdens and 31%-37%
reduction in fecal egg counts) and P values relative to either equal ratio combination of (0.33
mg/kg + 0.33 mg/kg) or (1 mg/kg + 1 mg/kg) (Fig 3A and 3B; Table 1; see Discussion).
1:1 ratio of Cry5B:tribendimidine drives cures from incomplete to
complete
These data demonstrate that a 1:1 mass ratio of the two drugs is highly synergistic. To see if we
could apply this information in a meaningful way, we tested whether the two compounds can
be combined at this ratio to drive an incomplete cure, which happens quite often in mass drug
administration of anti-nematode drugs, to complete cures. As shown in Fig 4A and 4B and S1
Table, either 10 mg/kg of Cry5B alone or 10 m/kg of tribendimidine alone gave incomplete
reductions in hookworm burdens (57% and 91%, respectively) and fecal egg counts (41% and
with a separate symbol, long horizontal bars represent mean hookworm burdens per group; small bars indicate standard error. (B), (D), and (F): Effects of
tribendimidine at indicated doses on parasite egg production (fecal egg counts) in hookworm-infected hamsters. For (B), (D), and (F) and in similar figures below,
shown are the average eggs per gram of feces in each group on day 4 post-treatment. The fecal egg counts in each animal are indicated with a separate symbol. Long
horizontal bars represent mean eggs per gram of feces (EPG) per group; small bars indicate standard error. Panel (A) & (B); (C) & (D) and (E) & (F) came from three
independent in vivo experiments. TrBD = tribendimidine.
https://doi.org/10.1371/journal.pntd.0006506.g001
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Fig 2. Dose response of Cry5B spore-crystal lysates (SCL) against hookworm A. ceylanicum infections in hamsters. Effects of Cry5B SCL at indicated
doses on (A) intestinal hookworm burdens and (B) fecal egg counts in hookworm-infected hamsters.
https://doi.org/10.1371/journal.pntd.0006506.g002
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Fig 3. Cry5B and tribendimidine in combination are synergistic in vivo against hookworm infections in hamsters. Effects of individual treatment of Cry5B alone or
tribendimidine alone and combination treatment of Cry5B plus tribendimidine at indicated doses on (A) intestinal hookworm burdens and (B) fecal egg counts in
hookworm-infected hamsters. Brackets indicate statistical comparisons between groups, with p values shown. Data come from the combination of two independent in
vivo experiments. TrBD = tribendimidine.
https://doi.org/10.1371/journal.pntd.0006506.g003
Fig 4. The 1:1 Cry5B:tribendimidine combination at a higher dose eliminates hookworm infections in hamsters. Effects of treatment of higher dose Cry5B alone or
higher dose tribendimidine alone or higher dose Cry5B plus higher dose tribendimidine in combination on (A) intestinal hookworm burdens and (B) fecal egg counts
in hookworm-infected hamsters. None of the individual drugs eradicated the hookworm infections in hamsters, but the combination of both drugs did.
TrBD = tribendimidine.
https://doi.org/10.1371/journal.pntd.0006506.g004
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91%, respectively). However, the combination of 10 mg/kg of Cry5B plus 10 m/kg of tribendi-
midine resulted in a complete cure (100% reduction) of the parasites based on hookworm bur-
dens and fecal egg counts (Fig 4A and 4B; S1 Table). The combination of 10 mg/kg Cry5B plus
10 mg/kg tribendimidine was even superior to 20 mg/kg of either compound alone (64%-99%
reduction in hookworm burdens and fecal egg counts).
Cry5B and pyrantel are synergistic in vivo
Although tribendimidine has good potential as a single dose anti-nematode drug for treatment
of hookworms and Ascaris [15–17] it is nonetheless not yet a WHO approved drug. The mech-
anistically related nAChR agonist, pyrantel, on the other hand, is WHO approved. Although
safe, pyrantel is not widely used because it has lower efficacy than BZs and is less conveniently
dosed based on weight, versus fixed dosage like BZs [56]. To see if Cry5B synergizes with pyr-
antel in vivo, we performed a similar study to that used for tribendimidine, beginning with an
in vivo pyrantel dose-response curve. We chose as our upper dose (strong effect) 9 mg/kg pyr-
antel based on previous literature [57] and then reduced subsequent doses by factors of three.
Relative to water (placebo) control, 0.33 mg/kg pyrantel (labeled PYR in the figure) showed no
significant impact on hookworm burdens (5% reduction, P = 0.87) whereas 1 mg/kg pyrantel
showed a trend toward lower burdens that was not statistically significant (39% reduction,
P = 0.22; Fig 5A; S1 Table). Looking at fecal egg counts, 0.33 mg/kg pyrantel showed a slight
impact (38% reduction) that was not statistically significant (P = 0.47) from water control and
was not different than other low doses like 0.037 mg/kg (31% reduction, P = 0.51; Fig 5B; S1
Table). Based on these data, we chose 0.33 mg/kg pyrantel as our no/low effect dose of this
drug.
A dose response of Cry5B (0.33, 1.0, 3.0 and 9.0 mg/kg) to hookworm infections in ham-
sters was then carried out without and with the chosen no/low effect dose of pyrantel (0.33
mg/kg), measuring hookworm burdens and fecal egg counts (Fig 6A and 6B; Table 2). Analy-
ses of these data revealed a striking result. Combination of Cry5B and pyrantel at a 3:1 mass
ratio (1 mg/kg Cry5B plus 0.33 mg/kg pyrantel) resulted in expulsion of parasites (58% reduc-
tion) that was beyond what was expected based on the effects of individual doses and statisti-
cally different from control (P = 0.031), even when each compound individually had no
impact on hookworm burdens (10–12% reduction, P = 0.74–0.78; Fig 6A; Table 2). Indeed, 1
mg/kg Cry5B plus 0.33 mg/kg pyrantel was superior even to the next highest dose of 3 mg/kg
Cry5B plus 0.33 mg/kg pyrantel (32% reduction, P = 0.35).
3:1 ratio of Cry5B:pyrantel drives cures from incomplete to complete
These data demonstrate that a 3:1 mass ratio Cry5B:pyrantel is synergistic. As above, to see if
we could apply this information in a meaningful way, we tested whether the two compounds
could be combined at this ratio to drive incomplete cures to complete cures. As shown in Fig
7A and 7B and S1 Table, 15 mg/kg of Cry5B and 5 m/kg of pyrantel individually gave incom-
plete reductions in hookworm burdens (51% and 93%, respectively) and fecal egg counts (55%
and 90%). However, the combination of the two resulted in a complete elimination of the para-
sites based on hookworm burdens and fecal egg counts (100% reductions; Fig 7A and 7B; S1
Table).
A parasite population resistant to pyrantel is hypersusceptible to Cry5B
relative to a non-resistant parasite population
In addition to synergy, another extremely useful property of drug combinations is hypersus-
ceptibility or collateral sensitivity [58]. Hypersusceptibility or collateral sensitivity refers to the
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Fig 5. Dose response of pyrantel against hookworm A. ceylanicum infections in hamsters. Effects of pyrantel at indicated doses
on (A) intestinal hookworm burdens and (B) fecal egg counts in hookworm-infected hamsters. PYR = pyrantel.
https://doi.org/10.1371/journal.pntd.0006506.g005
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phenomenon whereby development of resistance by a microbe or cancer cell to one drug
(drug A) results in increased sensitivity of the microbe or cancer to another drug (drug B) rela-
tive to the microbe (or cancer cell) not resistant to drug A. This relationship appears to be pre-
dictive of recalcitrance to resistance for both viruses and bacteria and is highly desirable
[21,59–61]. We had previously demonstrated that C. elegans resistant to nAChR agonists are
hypersusceptible to Cry5B and that C. elegans resistant to Cry5B are hypersusceptible to
nAChR agonists [32].
To confirm whether the same relationship exists with parasitic nematodes, we compared
the susceptibility of two populations of cyathostomins, small strongyle parasites of horse,
one strain of which (known as Population S) has increased resistance to the nAChR agonist
pyrantel, as well to BZs [36]. Cyathostomins are equine intestinal parasites related to human
hookworms—both are clade V nematodes in the suborder Strongylida. Since live adult
cyathostomin parasites are difficult to come by, we tested the ability of Cry5B to inhibit
Fig 6. Cry5B and pyrantel in combination are synergistic in vivo against hookworm infections in hamsters. Effects
of individual treatment of Cry5B alone or pyrantel alone and combination treatment of Cry5B plus pyrantel at
indicated doses on (A) intestinal hookworm burdens and (B) fecal egg counts in hookworm-infected hamsters. Black
arrow indicates the effect of the combination of Cry5B and pyrantel at ratio of 3:1 (1 mg/kg Cry5B + 0.33 mg/kg
pyrantel), showing greater than expected impact based on individual doses or next highest combination dose.
PYR = pyrantel.
https://doi.org/10.1371/journal.pntd.0006506.g006
Fig 7. The 3:1 Cry5B:pyrantel combination at a higher dose eliminates hookworm infections in hamsters. Effects of treatment of higher dose Cry5B alone or
higher dose pyrantel alone or higher dose Cry5B plus higher dose pyrantel in combination on (A) intestinal hookworm burdens and (B) fecal egg counts in
hookworm-infected hamsters. None of the drugs individually eradicated the hookworm infections in hamsters but the combination of both drugs did.
PYR = pyrantel.
https://doi.org/10.1371/journal.pntd.0006506.g007
Anti-hookworm combination therapy
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006506 May 18, 2018 15 / 22
development of cyathostomin eggs (isolated from feces) to the infectious third larval stage. In
this assay, we confirmed that, based on inhibitory concentration 50% (IC50) values, Population
S is indeed resistant to pyrantel relative to the non-resistant population (Fig 8A; Table 3;
P<0.001). Moreover, the pyrantel-resistant population, Population S, is hypersusceptible or
hypersensitive to Cry5B based on IC50 values relative to the non-resistant population (Fig 8B;
Table 3; P = 0.033).
Discussion
Here we demonstrate that Cry5B forms potent and unprecedented anti-nematode combina-
tion therapy with the nAChR agonists tribendimidine and pyrantel. This finding is based on
three findings. First, Cry5B synergizes with both drugs in vivo—a subtherapeutic dose of
Cry5B combined with a subtherapeutic dose of tribendimidine or pyrantel results in signifi-
cant reductions in hookworm burdens. This synergy appears at some, but not all, ratios of the
compounds. Second, proper ratio mixing of Cry5B with either tribendimidine or pyrantel can
drive incomplete cures to complete cures and can be superior to either drug alone at double
the dose (tested with Cry5B and tribendimidine). Third, a parasite population resistant to
nAChR agonists are hypersusceptible to Cry5B relative to a non-resistant population based on
IC50 values. There are several caveats to these data. First, the two populations are not isogenic.
Second, cyathostomin populations are a complex mixture of species. Third, the nAChR-resis-
tant cyathostomin parasites tested (Populations S) are also resistant to BZs. BZ resistance
could also contribute to the Cry5B hypersusceptible phenotype, although we noted that a C.
elegans mutant resistant to BZs is not hypersusceptible to Cry5B [32]. Taken together, our
cyathostomin data are consistent with our C. elegans data showing the hypersusceptibility of
nAChR-resistant nematodes to Cry5B [32] and indicate that additional testing of nAChR-
resistant parasite isolates is warranted to further confirm these results.
Based on our data, a 1:1 mass ratio of Cry5B:tribendimidine and 3:1 mass ratio of Cry5B:
pyrantel shows more synergy than other ratios tested. This point is dramatically made by the
finding that, for example, 0.33 mg/kg Cry5B plus 0.33 mg/kg tribendimidine is superior to
0.33 mg/kg Cry5B plus 1 mg/kg tribendimidine, despite the fact that the latter is higher in
dose. Consistent with this finding, we find that 10 mg/kg Cry5B plus 10 mg/kg tribendimidine
Fig 8. Pyrantel-resistant cyathostomins are hypersusceptible to Cry5B. Dose-dependent developmental inhibition of a non-anthelmintic
resistant population of cyathostomins (Barn 10; [62]) and of an anthelmintic-resistant population of cyathostomins (pyrantel-resistant Population S
or PYR_R) to (A) pyrantel and (B) purified Cry5B. Each data point represents the % of larvae that matured to the infectious L3 stage (L3i). Error
bars indicate standard error from three independent replicates. Susep = Barn 10, pyrantel susceptible; PYR_R = pyrantel-resistant population.
https://doi.org/10.1371/journal.pntd.0006506.g008
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not only drives incomplete cures to complete cures but is superior to 20 mg/kg of either drug
alone. Similarly for Cry5B plus pyrantel, 1 mg/kg Cry5B plus 0.33 mg/kg pyrantel is more
potent than 3 mg/kg Cry5B plus 0.33 mg/kg pyrantel, despite the fact the latter is higher in
dose.
These findings underscore the importance of setting the right ratios of drugs for combina-
tion therapy, as has been previously noted [63,64]. As we do not know the mechanism by
which Cry5B and nAChR agonists might synergize, we can only speculate as to why some dose
ratios are synergistic but others, including ones with higher doses, are not. As noted in Tardi
et al., for example, cells can have different cellular responses to drug B at low dose versus at
high dose. Drug A’s effects might be enhanced by the low-dose cellular response to drug B but
not by the high-dose cellular response to drug B. Our data suggest efforts underway to com-
bine anti-nematode drugs clinically [16,23–27] would benefit from preliminary studies such as
those carried out here to determine which ratio of drugs achieves the best efficacy. By varying
the ratios tested, it is possible that better clinical effects against parasites could be achieved
than those seen now.
As for any infectious diseases (e.g., HIV, malaria, TB, STNs), resistance to drugs is of para-
mount importance. The hypersusceptibility to Cry5B seen here (also known as collateral sensi-
tivity) for parasites resistant to nAChR agonists has important implications for resistance.
Studies done with antibiotic-resistant bacteria predict that hypersusceptibility (or collateral
sensitivity) is a highly desirable trait and correlates with delayed evolution of resistance to a
drug combination [58,65,66]. Thus, we predict that Cry5B and nAChR agonists such as triben-
dimidine and pyrantel would have longer efficacy and delayed resistance.
Our synergy findings also have implications for the development of resistance. Synergy can
either have a positive effect on delaying evolution of drug resistance or a negative effect (speed-
ing up drug resistance) depending upon the effect that synergy has upon target microbe/para-
site reproduction [67,68]. If the effects on reproduction of the target microbe/parasite are
above a certain threshold, then synergy delays resistance (by limiting reproduction cycles). If,
however, the effects on reproduction are below a threshold, then synergy speeds up resistance
(since resistance to one of the drugs in the combination also removes the synergistic effect). In
the case of Cry5B plus tribendimidine or pyrantel, our high dose combination data suggest
that the synergy might have a positive effect on delaying resistance since hookworms are obli-
gate parasites—complete elimination from the host blocks the reproductive cycle. Our high-
dose results with Cry5B and nAChR agonists are consistent with recent modeling work that
predicts the benefits of combining two anthelmintics at high efficacy doses with regards to
delaying resistance [69,70].
In summary, we find that the combination of Cry5B with nAChR agonists, either tribendi-
midine or pyrantel, has powerful characteristics predicted to have excellent clinical efficacy
and delayed resistance. Given that neither nAChR agonists nor Cry5B are widely used thera-
peutically against STNs, it would be ideal to deploy the combination as soon as possible to get
the maximal benefit from the therapy before the parasites have time to develop resistance to
either one. Furthermore, given the widespread use of nAChR agonists in veterinary medicine,
Cry5B combinations could provide significant benefits for animal husbandry where anti-nem-
atode drug resistance is rampant.
Supporting information
S1 Fig. Cry5B and tribendimidine (TrBD) combination studies in vivo against hookworm
infections in hamsters. Hookworm burdens (A) and fecal egg counts (B) of infected hamsters
treated with a range of Cry5B doses alone and in combination with two no-effect doses of
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TrBD. Hookworm burdens (C) and fecal egg counts (D) of infected hamsters treated with a
range of TrBD doses alone and in combination with two no-effect doses of Cry5B. Arrows
indicate the combinations of Cry5B and TrBD at ratio of 1:1 (0.33 mg/kg Cry5B + 0.33 mg/kg
Cry5B and 1 mg/kg Cry5B + 1 mg/kg Cry5B), showing stronger-than-expected reductions in
both measures of parasitism.
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S1 Table. In vivo data associated with experimental results in Figs 1, 2, 4, 5 and 7.
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S2 Table. In vivo data associated with experimental results in S1 Fig.
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S3 Table. 95% confidence limits associated with experimental results in Tables 1, 2, S1 and
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